

13 MAY 2026

PACIFIC EDGE PLACEMENT INCREASED TO NZ\$25.4 MILLION

DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge Limited (**Pacific Edge** or the **Company**) (NZX/ASX: PEB) today announces it has successfully raised NZ\$25.4 million of new equity in a placement of new ordinary shares (**Placement**), after the Directors resolved to increase the Placement and accept oversubscriptions following strong investor demand.

The Placement, which was well supported by existing institutional and other investors, was completed on Tuesday, 12 May 2026. It was priced at NZ\$0.17 per share, a 2.3% discount to the closing share price on 8 May 2026, prior to the announcement of the company’s planned equity issue.

As previously announced, Pacific Edge intends to conduct a retail offer to eligible existing shareholders to raise up to NZ\$6 million at the same offer price of NZ\$0.17 per share (with the ability to accept oversubscriptions at Pacific Edge’s discretion) (**Retail Offer**). Full details of the Retail Offer will be set out in the Retail Offer Document, which will be released to the NZX and ASX, and sent to eligible shareholders on Thursday, 14 May 2026.

The Placement and Retail Offer are aimed at ensuring Pacific Edge has additional resources and capacity to support ongoing operations and growth, support the company to achieve Medicare re-coverage, and continue evidence generation, product development and innovation.

Chairman, Simon Flood said: “We are delighted with the investor support we have received. The new capital will allow us to consolidate our market position in bladder cancer diagnostics. It will support the Company and its operations to regain Medicare coverage and assist our move towards the broader adoption of our tests by commercial payers in the US and further afield. We are determined not to lose that momentum.”

Pacific Edge Chief Executive, Dr Peter Meintjes, said: “The robust evidence emerging from our clinical evidence program is shifting clinical sentiment towards the broader adoption of our tests with opportunities in the US and in the Asia Pacific Region. We are delighted with the strong support we have received from investors in the Placement to continue to pursue our plans, and we are looking forward to making the Retail Offer to eligible shareholders at the same offer price.”

Pacific Edge is advised on the equity raise by Cameron Partners (investment banking advisers), Harnos Horton Lusk (legal advisers) and The Project (investor relations and communications advisers).

For further information on the detail and timetable of the equity raising please refer to the announcement and presentation dated Friday, 8 May 2026 and released by NZX and ASX on Monday, 11 May 2026.

Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.

For more information:

Investors:

Dr Peter Meintjes
Chief Executive
Pacific Edge
P: 022 032 1263

Media:

Richard Inder
The Project
P: +64 21 645 643

OVERVIEW OF PACIFIC EDGE

Pacific Edge: www.pacifiedgedx.com

Pacific Edge Limited (NZX/ASX: PEB) is a global cancer diagnostics company leading the way in the development and commercialization of bladder cancer diagnostic and prognostic tests for patients presenting with hematuria or surveillance of recurrent disease. Headquartered in Dunedin, New Zealand, the company provides its suite of Cxbladder tests globally through its wholly owned, and CLIA certified, laboratories in New Zealand and the USA.

Cxbladder: www.cxbladder.com

Cxbladder is a suite of non-invasive genomic urine tests optimized for the risk stratification of urothelial cancer in patients presenting with microhematuria and those being monitored for recurrent disease. The tests help improve the overall patient experience, while prioritizing time and clinical resources to optimize practice workflow and improve efficiency.

Supported by over 20 years of research, Cxbladder's evidence portfolio extends to more than 25 peer reviewed publications, and Cxbladder Triage is now included in the American Urological Association's Microhematuria Guideline. To drive increased adoption and improved patient health outcomes, Cxbladder is the focal point of numerous ongoing and planned studies designed to generate further clinical utility evidence.

Cxbladder is available in the US, Australasia, and Israel and in markets throughout Asia and South America. In the US, the test has been used by over 5,000 urologists who have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to around 70% of the population via public healthcare and all residents have the option of buying the test online.